|

Doxorubicin Clinical Trials

94 actively recruiting trials across 28 locations

▼ -2 trials since July 2026

Also known as: 14-Hydroxydaunomycin, 23214-92-8, ABVD, ADM; Adriamycin; DOX; Doxorubin hydrochloride, ADRIAMYCIN® +21 more

Pipeline

Early 1: 2Phase 1: 15Phase 2: 37Phase 3: 29Phase 4: 1Phase 1/2: 7

Top Sponsors

  • National Cancer Institute (NCI)7
  • University of Washington5
  • Memorial Sloan Kettering Cancer Center4
  • M.D. Anderson Cancer Center4
  • University of Birmingham3

Indications

  • Cancer94
  • Breast Cancer12
  • Diffuse Large B-cell Lymphoma(DLBCL)5
  • Hodgkin Lymphoma4
  • Diffuse Large B-Cell Lymphoma4

Other36 trials

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Phase 4
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/2
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Phase 3
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Phase 2
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
Phase 2
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Phase 3
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Phase 2
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Phase 1/2
Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Phase 2
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
Phase 3
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
Phase 1
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Phase 2
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Phase 3
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Phase 2
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Phase 2
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Phase 3
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Phase 1
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Phase 3
RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Phase 2
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Phase 2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Phase 2
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Phase 2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1/2
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Phase 3
Using Tumor Models to Determine Treatments
Phase 2

Birmingham, Alabama13 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Hospital of Alabama

Phase 3
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Children's Hospital of Alabama

Phase 2
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Local Institution - 0225

Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

University of Alabama

Early 1
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

University of Alabama

Phase 1
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

University of Alabama at Birmingham Cancer Center

Phase 3
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

University of Alabama at Birmingham (Children's of Alabama)

Phase 1
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Hospital of Alabama

Phase 3
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Houston, Texas5 trials

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

MD Anderson Cancer Center

Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Harris Health System - Smith Clinic

Phase 2
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

MD Anderson Cancer Center

Phase 2
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M D Anderson Cancer Center

Phase 2

Seattle, Washington5 trials

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1

Miami, Florida3 trials

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

University of Miami

Phase 2
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

University of Miami Miller School of Medicine

Early 1
BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma

University of Miami

Phase 2

Mobile, Alabama2 trials

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Infirmary Cancer Care ( Site 0157)

Phase 2
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

USA Mitchell Cancer Institute ( Site 0173)

Phase 3

Scottsdale, Arizona2 trials

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Mayo Clinic - Arizona

Phase 3
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Mayo Clinic in Arizona

Phase 1/2

Tucson, Arizona2 trials

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

University of Arizona Cancer Center

Phase 3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Research Site

Phase 3

Duarte, California2 trials

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

Phase 1
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

City of Hope Medical Center

Phase 1

Stanford, California2 trials

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Stanford University - (Stanford Cancer Institute)

Phase 3
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Stanford Medical Center

Phase 2

Bethesda, Maryland2 trials

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

National Institutes of Health Clinical Center

Phase 1
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center

Phase 1

Boston, Massachusetts2 trials

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site

Phase 1/2
The CARDIOPROTECT Trial

Beth Israel Deaconess Medical Center

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Gilbert, Arizona1 trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Banner MD Anderson Cancer Center ( Site 0066)

Phase 3

Phoenix, Arizona1 trial

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Mayo Clinic Hospital in Arizona

Phase 3

Fresno, California1 trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

UCSF Fresno /ID# 264712

Phase 3

San Francisco, California1 trial

Venetoclax Basket Trial for High Risk Hematologic Malignancies

University of California San Francisco-Benioff Children's Hospital

Phase 1

Aurora, Colorado1 trial

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

University Of Colorado Hospital

Phase 2

New Haven, Connecticut1 trial

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Yale University School of Medicine

Phase 3

Washington D.C., District of Columbia1 trial

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Georgetown Lombardi Comprehensive Cancer Center

Phase 1

Tampa, Florida1 trial

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

St. Joseph's Children's Hospital

Phase 2

Atlanta, Georgia1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Children's Healthcare of Atlanta

Phase 1/2

Chicago, Illinois1 trial

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

University of Chicago Medical Center

Phase 1

Baltimore, Maryland1 trial

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

East Setauket, New York1 trial

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

North Shore Hematology Oncology Associates

Phase 1

New York, New York1 trial

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2

Portland, Oregon1 trial

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

OHSU Knight Cancer Institute

Phase 1/2

Nashville, Tennessee1 trial

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt University/Ingram Cancer Center

Phase 2

San Antonio, Texas1 trial

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

University Hospital System

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.